Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Proteomics Analysis of Human Tears in the Diagnosis and Management of Dry Eye Disease

NCT: NCT07175909 · COMPLETED

NCT IDNCT07175909
StatusCOMPLETED
Start Date2021-01-01
Completion2025-12-31
SponsorThe Hong Kong Polytechnic University (OTHER)
First posted
Last updated

Brief Summary

In this study, the initial tear proteome profiles in Dry Eye Disease (DED) patients, the safety and effectiveness of using an EC certificate DED treatment device in DED management, together with the associated global tear proteome changes, will be investigated.

Frequently Asked Questions

What is Proteomics Analysis of Human Tears in the Diagnosis and Management of Dry Eye Disease?

Proteomics Analysis of Human Tears in the Diagnosis and Management of Dry Eye Disease is a clinical trial registered under NCT07175909. Current status: COMPLETED.

What is the status of NCT07175909?

The current status of NCT07175909 (Proteomics Analysis of Human Tears in the Diagnosis and Management of Dry Eye Disease) is: COMPLETED.

When did Proteomics Analysis of Human Tears in the Diagnosis and Management of Dry Eye Disease start?

Proteomics Analysis of Human Tears in the Diagnosis and Management of Dry Eye Disease started on 2021-01-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.